Novavax
NVAX
$10.12
+8.00%
Novavax Inc is a biotechnology company focused on developing vaccines, operating in the clinical stage with a proprietary technology platform aimed at preventing a broad range of infectious diseases. The company is a niche player in the vaccine space, leveraging its recombinant protein nanoparticle technology to differentiate itself from mRNA-based competitors like Moderna and Pfizer. Currently, the investor narrative centers on the company's recent quarterly sales that more than doubled analyst expectations, signaling a potential turnaround, while also facing competitive pressures and the need to sustain growth beyond its COVID-19 vaccine. The stock's recent rally reflects renewed optimism about its commercial execution and pipeline prospects, but questions remain about long-term sustainability and market share in a post-pandemic environment.…
NVAX
Novavax
$10.12
Related headlines
Investment Opinion: Should I buy NVAX Today?
Based on the analysis, I rate NVAX as a Hold. The stock has a 'Buy' consensus from analysts with an average target price of $14.00, implying 57% upside, but the negative forward PE and high short interest introduce significant uncertainty. The recent revenue beat and strong margins are encouraging, but the market's skepticism about future earnings is a major concern. The stock is trading at a trailing PE of 2.47x, which is extremely low, but this is likely justified by the expected earnings decline. If the company can sustain its profitability and grow revenue, the stock could be undervalued, but if earnings turn negative, the stock could fall to its 52-week low of $6.20, representing a 31% downside from the current price of $8.94. I would upgrade to Buy if the forward PE turns positive and revenue growth continues, but downgrade to Sell if the company reports another quarter of losses or loses market share to competitors. Overall, the stock is fairly valued given the high risk profile.
Sign up to view all
NVAX 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The recent revenue beat and strong margins are positive, but the negative forward PE and high short interest suggest that the market is skeptical about sustainability. The stock's high beta and volatile price action add to the uncertainty. I would upgrade to bullish if the company reports another quarter of positive earnings and revenue growth, or if the forward PE turns positive. I would downgrade to bearish if the company reports a loss or if competitive pressures intensify.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Novavax's 12-month outlook, with a consensus price target around $14.00 and implied upside of +38.4% versus the current price.
Average Target
$14.00
0 analysts
Implied Upside
+38.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$7 - $25
Analyst target range
The wide spread between the low and high targets reflects divergent views on Novavax's ability to sustain growth and compete in the vaccine market. The high target of $25.00 likely assumes successful pipeline development and market share gains, while the low target of $7.00 suggests concerns about competitive pressures and revenue decline. The consensus leans bullish, but the high short interest ratio of 13.83 indicates that many investors are betting against the stock, adding to volatility. Recent news of a quarterly sales beat may prompt upgrades, but the lack of institutional ratings data limits further insight into recent rating changes.
Bulls vs Bears: NVAX Investment Factors
Novavax presents a high-risk, high-reward investment case. The bull case is anchored by a massive revenue beat, exceptional margins, and a deeply discounted trailing valuation, while the bear case is driven by a negative forward PE, high short interest, and competitive threats. Currently, the evidence slightly favors the bulls given the recent earnings momentum and analyst optimism, but the sustainability of profitability is the key tension. If the company can maintain its revenue trajectory and prove that the positive earnings are not a one-off, the stock could re-rate significantly higher. Conversely, if earnings revert to losses as the forward PE suggests, the stock could fall back toward its 52-week low. The most critical factor to watch is whether Novavax can secure additional partnerships or pipeline successes to diversify beyond its COVID-19 vaccine.
Bullish
- Revenue Beat and Turnaround: Novavax reported quarterly sales that more than doubled analyst expectations on May 8, 2026, signaling a potential inflection point. This beat drove the stock up over 6% on the day and contributed to a 13% monthly gain, indicating renewed commercial momentum.
- Exceptional Profitability Metrics: The company boasts a gross margin of 93.67% and an operating margin of 50.14%, reflecting strong unit economics and efficient cost management. Net margin is 39.19%, with positive EPS of $0.40, demonstrating that the business can be highly profitable when revenue materializes.
- Attractive Valuation on Trailing Earnings: With a trailing PE of 2.47x, the stock is trading at a significant discount to the broader market and its own history. This low multiple suggests the market is pricing in a sharp earnings decline, but if the recent profitability persists, the stock could be deeply undervalued.
- Analyst Consensus and Target Upside: Analysts rate the stock a 'Buy' with an average target price of $14.00, implying approximately 57% upside from the current price of $8.94. The high target of $25.00 suggests potential for more than 180% upside if pipeline and commercial execution exceed expectations.
Bearish
- Forward PE Negative Signals Earnings Decline: The forward PE is -14.56x, indicating that analysts expect earnings to turn negative in the coming year. This stark contrast with the trailing PE of 2.47x suggests that the current profitability is viewed as unsustainable, likely due to one-time items or declining COVID-19 vaccine demand.
- High Short Interest and Volatility: The short interest ratio is 13.83, meaning it would take nearly 14 days for short sellers to cover their positions. This high level of bearish sentiment, combined with a beta of 2.416, makes the stock highly volatile and prone to sharp swings, which could deter risk-averse investors.
- Negative Equity and Debt Concerns: The debt-to-equity ratio is -1.95, indicating negative shareholder equity, which is a red flag for financial stability. This suggests the company has accumulated losses exceeding its equity base, potentially limiting its ability to raise capital or weather future downturns.
- Relative Underperformance Over Longer Periods: Despite the recent rally, the stock has underperformed the S&P 500 by 3.31% over the past year and by 13.90% over the past six months. This longer-term weakness suggests that the recent uptick may be a temporary bounce rather than a sustained trend.
NVAX Technical Analysis
Novavax's stock has exhibited a volatile, range-bound trend over the past year, with a 1-year price change of +17.17% as of August 21, 2026. The current price of $8.94 sits at approximately 74.7% of its 52-week range (low of $6.20, high of $11.97), indicating a mid-range position that suggests neither extreme momentum nor deep value. This positioning implies the market is still undecided, with the stock having recovered from its lows but failing to break out to new highs, reflecting a consolidation phase.
Beta
2.42
2.42x market volatility
Max Drawdown
-35.9%
Largest decline past year
52-Week Range
$6-$12
Price range past year
Annual Return
+35.5%
Cumulative gain past year
| Period | NVAX Return | S&P 500 |
|---|---|---|
| 1m | +38.3% | +2.0% |
| 3m | -0.8% | +1.0% |
| 6m | +1.3% | +11.8% |
| 1y | +35.5% | +18.1% |
| ytd | +41.9% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NVAX Fundamental Analysis
Novavax's revenue trajectory has been highly volatile, with the most recent quarter showing a dramatic beat, as sales more than doubled analyst expectations (reported on May 8, 2026). However, the company's multi-quarter trend is difficult to assess due to limited data, but the recent surge suggests a potential inflection point. The company's gross margin is exceptionally high at 93.67%, indicating strong unit economics, but net income is positive with an EPS of $0.40, driven by a net margin of 39.19%. Operating margin stands at 50.14%, reflecting efficient cost management, though these figures may be influenced by one-time items or licensing revenues.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NVAX Overvalued?
Given that Novavax has positive net income (EPS of $0.40), the PE ratio is the primary valuation metric. The trailing PE is 2.47x, which is extremely low, while the forward PE is -14.56x, indicating that analysts expect future earnings to turn negative, a stark contrast that suggests the market is pricing in a significant earnings decline. This discrepancy implies that the current profitability may be unsustainable, and the market is skeptical about future earnings power.
PE
2.5x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
2.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant for Novavax. The company's negative debt-to-equity ratio of -1.95 indicates that it has more liabilities than assets, a precarious position that could limit its financial flexibility. While the recent quarter showed positive EPS of $0.40 and a net margin of 39.19%, the forward PE of -14.56x suggests that analysts expect a return to losses, which could be driven by declining COVID-19 vaccine sales or increased R&D spending. The company's high gross margin of 93.67% is impressive, but it may not be sustainable if revenue concentration in a single product (COVID-19 vaccine) leads to volatility. Additionally, the negative price-to-cash-flow ratio of -4.45 indicates that the company is not generating positive cash flow, which could necessitate future dilution or debt financing.
FAQ
The key risks of holding NVAX include: 1) Financial risk: negative debt-to-equity ratio of -1.95 and negative cash flow, which could lead to dilution or financial distress. 2) Competitive risk: intense competition from mRNA vaccines by Moderna and Pfizer, which have larger market shares and more resources. 3) Market risk: high beta of 2.416 and short interest ratio of 13.83, making the stock highly volatile and susceptible to sharp declines. 4) Company-specific risk: reliance on a single product (COVID-19 vaccine) and uncertainty about pipeline success. The most severe risk is a return to losses, which could send the stock to its 52-week low of $6.20, a 31% downside from the current price.
The 12-month forecast for NVAX is uncertain. In the bull case (25% probability), the stock could reach $14-$25, driven by sustained revenue growth and pipeline success. In the base case (50% probability), the stock is expected to trade between $8 and $14, with the average analyst target of $14.00 as the upper bound. In the bear case (25% probability), the stock could fall to $6.20-$8.00 if earnings turn negative or competitive pressures intensify. The most likely scenario is the base case, where the stock remains volatile but trades within a range. Investors should monitor quarterly earnings and pipeline developments to adjust their expectations.
NVAX is trading at a trailing PE of 2.47x, which is extremely low and suggests the stock is undervalued on a trailing basis. However, the forward PE is -14.56x, indicating that analysts expect earnings to turn negative, which would make the stock appear overvalued on a forward basis. The PS ratio is 0.97x, which is reasonable for a biotech company. Relative to its own history, the stock is trading at 74.7% of its 52-week range, suggesting it is neither at extreme highs nor lows. The market is pricing in a significant earnings decline, which may or may not materialize. If the company can sustain its profitability, the stock is undervalued; if not, it is fairly valued or overvalued.
NVAX is a high-risk, high-reward stock. Analysts have a 'Buy' rating with an average target price of $14.00, implying 57% upside from the current price of $8.94. However, the forward PE is negative, indicating expected earnings decline, and the short interest ratio is high at 13.83. The stock could be a good buy for investors who believe the recent revenue beat is sustainable and that the company can overcome competitive pressures. However, it is not suitable for risk-averse investors due to its high volatility and financial instability. If you have a high risk tolerance and a long-term horizon, NVAX could be a speculative addition to your portfolio, but it should be sized appropriately.
NVAX is more suitable for short-term trading than long-term investment due to its high volatility (beta of 2.416) and uncertain earnings outlook. The stock has a beta of 2.416, meaning it is 2.4 times more volatile than the market, which can lead to large price swings. The company's financial instability and competitive pressures make it risky for long-term holders. However, if you believe in the company's technology and pipeline, a long-term investment could pay off if the company achieves sustained profitability. Given the high risk, a minimum holding period of 3-5 years would be required to allow the pipeline to develop, but short-term traders could capitalize on volatility. The stock pays no dividend, so returns are entirely dependent on price appreciation.